创新药迎多重利好,券商看好投资机会

制药网
Nov 04, 2025

在全球医药产业格局重塑与国内政策红利持续释放的双重背景下,中国创新药产业正迎来新的发展机遇期。券商机构普遍看好这一赛道的投资价值,其中国金证券明确指出,创新药主线及左侧板块困境反转将是2025-2026年医药板块的最大投资机会。当前,全链条创新优势凸显、国际化进程加速、政策精准赋能的多重利好共振,正推动中国创新药从“跟跑”向“并跑”“领跑”跨越,医疗行业也由此站上新的发展起点,即将开启新一轮增长...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10